Alembic Pharmaceuticals receives USFDA Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 %
Deepthi | Myequity news | Date : 10-12-2018 10:55:00 IST
Alembic Pharmaceuticals Limited today announced that the company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 %. Olopatadine hydrochloride ophthalmic solution USP, 0.1 % is indicated for the treatment of the signs and symptoms of allergic conjunctiviti's.
Olopatadine hydrochloride ophthalmic solution USP. 0.1 %, have an estimated market size of US$ 61 million for twelve months ending December 2017 according to IQVIA.
About Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.